Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology

Contributed by: PR Newswire

Tags

EditForce-PPR

More Like This

PR Newswire associated0

ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

PR Newswire associated0

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress

Release Therapeutics Secures CHF 3.3 Million in Seed Funding

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

PR Newswire associated0

The Department of Health - Abu Dhabi provides gene therapy for Duchenne Muscular Dystrophy for the first time in Abu Dhabi and outside the US